Biocon and its partner, Quark Pharmaceuticals, have received approval from the Drug Controller General of India (DCGI) to proceed with the study, the first ever clinical trial of a siRNA therapy in India.
Drug Controller General of India
RECOMMENDED POSTS
Subscribe with us
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
Also Join: 
.png)
